Virtual Presentation

Rituximab resistance and the US clinical experience with Bendamustine

CME Program Director: Stephanie A. Gregory, MD

Faculty: Jonathan W. Friedberg, MD

CME CREDIT INFORMATION

Release Date: 03/15/07

Expiration Date: 03/14/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain some of the mechanisms of resistance to rituximab
Discuss the single-agent use of bendamustine in the United States in relapsed indolent or transformed NHL
Compare the US experience with bendamustine to that of ⁹⁰[Y]- ibritumomab and ¹³¹[I]-tositumomab

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Sponsored for CME credit by Rush University Medical Center.

Supported by an unrestricted educational grant from:

Educational grants support only the CME-certified components of this program.